Tissue Regenix promotes new CEO from within
November 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, tissue regenix
Just over two weeks ago, Tissue Regenix announced that its long-standing CEO, Antony Odell, would be leaving the company. It …
FDA issues warnings in crackdown on baseless cannabis miracle cures
November 2, 2017Research and Development, Sales and Marketing FDA, cannabidiol, cannabis, pharma
The FDA has issued a warning over cannabis-based therapies which promise the ability to cure cancer, asserting that such treatments …
Sanofi Q3 results disappoint due to waning diabetes sales
November 2, 2017Sales and Marketing Lantus, Sanofi, diabetes, pharma
Sanofi readjusted its 2017 financial expectations after its third-quarter results came in lower than projected. The company revealed that net …
New test could determine womens’ risk of miscarriage or premature birth
November 2, 2017Research and Development biotech, drugs, pharma, pharmaceutical, pregnancy
Scientists in the US have reported findings suggesting that certain molecules in the blood are strongly associated with complications during …
Allergan ready to take a loss by selling Teva shares
November 2, 2017Sales and Marketing Allergan, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million …
Novartis reveals the data behind its showdown with Gilead
November 1, 2017Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical
Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …
Topas Therapeutics brings in new CMO
November 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Topas Therapeutics, biotech, drugs, pharma, pharmaceutical
Topas Therapeutics, a German company focused on developing novel therapeutics to treat immune-mediated and autoimmune diseases, announced that it has …
CAR-T is bringing true precision to the fight against cancer
November 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …
Roche’s Tecentriq approved for funding in UK in bladder cancer
November 1, 2017Research and Development, Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical
In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the …
Indivior’s opioid addiction treatment recommended by FDA advisory panel
November 1, 2017Research and Development, Sales and Marketing FDA, RGP-6000, Trump, US, indivior, opioid crisis, opioids
Another step has been made in the fight back against the ongoing opioid crisis in the US as it emerges …
CEO and President implicated as price-fixing probe widens
November 1, 2017Research and Development, Sales and Marketing Mylan, Teva, biotech, drugs, pharma, pharmaceutical
A group of states, 45 members-strong, has expanded its probe into the generics pharmaceutical industry by expanding its case to …
AstraZeneca asthma therapy tralokinumab flops at Phase 3
November 1, 2017Research and Development AstraZeneca, MedImmune, asthma, pharma
AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab …
Cancer death rates 61% higher in poorer areas
November 1, 2017Medical Communications, Research and Development NHS, biotech, drugs, pharma, pharmaceutical
Figures released by NHS Scotland have revealed that the numbers of deaths from cancer are 67% higher in the poorest …
Shire to streamline operations with 100-strong plant sale and in-house Cinryze production
October 31, 2017Manufacturing and Production, Sales and Marketing Cinryze, Shire, pharma
Shire has revealed that it plans to sell one of its manufacturing sites in Milford, Massachusetts, having already entered active …
Over-the-counter multinutrient drink could have beneficial impact on Alzheimer’s, new study reveals
October 31, 2017Manufacturing and Production, Research and Development Alzheimer's, Fortasyn Connect, Souvenaid, dementia
LipiDiDiet, a European project investigating “the impact of nutritional lipids on neuronal and cognitive performance in ageing, Alzheimer’s disease and …
Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma
October 31, 2017Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis
Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …
Kirin Holdings to withdraw from 30 year venture with Amgen, sell shares for $780m
October 31, 2017Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Kirin, joint venture, pharma
Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would …
Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal
October 30, 2017Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …
MSD withdraws European application of Keytruda combo in lung cancer
October 30, 2017Sales and Marketing EMA, MSD, keytruda
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …
AstraZeneca licenses genetic disease drug to Mereo Biopharma for $5 million, becomes shareholder
October 30, 2017Sales and Marketing AstraZeneca, Mereo BioPharma, pharma
AstraZeneca has agreed to license AZD9668, its experimental drug for the treatment of alpha-1 antitrypsin deficiency, to Mereo Biopharma for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
